EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieKohortenstudieOpen Access · CC BY-NC 4.0

Effects of sacubitril/valsartan on renal function and outcome in patients with heart failure and reduced ejection fraction: an Italian cohort study

Alberto Palazzuoli iD, Filippo Pirrotta, Alessandra Cartocci, Elvira Delcuratolo, Frank Loyd Dini, Michele Correale, Giuseppe Dattilo, Daniele Masarone, Laura Scelsi, Stefano Ghio, Carlo Gabriele Tocchetti, Valentina Mercurio und 5 weitere

Therapeutic Advances in Cardiovascular Disease · 2024-01 · 18

DOI: 10.1177/17539447241285136 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Therapeutic Advances in Cardiovascular Disease, online erschienen am 29.11.2024. Verfasst von Alberto Palazzuoli und 16 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Diseases Unit, Cardio Thoracic and Vascular Department, Le Scotte Hospital University of Siena, Viale Bracci, Siena 53100, Italy. Hauptthemen laut MEDLINE: Aminobutyrates, Biphenyl Compounds, Drug Combinations, Heart Failure. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sacubitril/valsartan (S/V) is a cornerstone treatment for heart failure (HF). Beneficial effects on hospitalization rates, mortality, and left ventricular remodeling have been observed in patients with heart failure and reduced ejection fraction (HFrEF). Despite the positive results, the influence of S/V on renal function during long-term follow-up has received little attention.

Aims

We investigated the long-term effects of S/V therapy on renal function in a large cohort of patients with HFrEF. Additionally, we examined the effects of the drug in patients with chronic kidney disease (CKD) compared to those with preserved renal function and identified primary risk characteristics Methods: We studied 776 outpatients with HFrEF and left ventricular ejection fraction (LVEF) 1000 pg/ml (HR 1.95[1.38, 2.77], p < 0.001), furosemide dose >50 mg (HR 2.04 [1.48, 2.82], p < 0.001), and creatinine values >1.5 mg/dl occurred during follow-up (HR 1.74 [1.24, 2.43], p < 0.001) were linked to increased risk. At multivariable analysis, increased doses of loop diuretics, advanced NYHA class, creatinine >1.5 mg/dl, and atrial fibrillation were independent predictors of adverse events.

Conclusion

Long-term S/V therapy is associated with improved outcomes and renal protection in patients with HFrEF. This effect is more pronounced in patients who tolerate escalating doses. The positive effects of the drug are maintained in both CKD and preserved renal function. Future research may study the safety and underlying causes of current protection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminobutyratesBiphenyl CompoundsDrug CombinationsHeart FailureRegistriesRenal Insufficiency, ChronicValsartanAgedAged, 80 and overFemaleHumansMaleMiddle AgedAngiotensin II Type 1 Receptor BlockersAngiotensin Receptor AntagonistsGlomerular Filtration RateItalyKidneyNeprilysinProtease InhibitorsRisk FactorsStroke VolumeTetrazolesTime FactorsTreatment OutcomeVentricular Function, Left

Stichwörter der Autor:innen

heart failureoutcomerenal functionsacubitril/valsartan

Substanzen

AminobutyratesAngiotensin II Type 1 Receptor BlockersAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug CombinationsNeprilysinProtease Inhibitorssacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartan

Autor:innen und Institutionen

  • Cardiovascular Diseases Unit, Cardio Thoracic and Vascular Department, Le Scotte Hospital University of Siena, Viale Bracci, Siena 53100, Italy.
  • Cardiovascular Diseases Unit, Cardio Thoracic and Vascular Department, Le Scotte Hospital University of Siena, Siena, Italy.
  • Department of Medical Science, Surgery and Neurosciences, University of Siena, Siena, Italy.
  • Cardio Thoracic and Vascular Department, University of Pisa, Pisa, Italy.
  • Department of Cardiology, University Hospital Foggia, Foggia, Italy.
  • Department of Biomedical, Dental Sciences, and Morphofunctional Imaging, University of Messina, Messina, Italy.

ORCID-Profile: Alberto Palazzuoli

Zitieren

APA

Palazzuoli, A., Pirrotta, F., Cartocci, A., Delcuratolo, E., Dini, F. L., Correale, M., Dattilo, G., Masarone, D., Scelsi, L., Ghio, S., Tocchetti, C. G., Mercurio, V., Brunetti, N. D., Nodari, S., Barillà, F., Ambrosio, G., & Carluccio, E. (2024). Effects of sacubitril/valsartan on renal function and outcome in patients with heart failure and reduced ejection fraction: an Italian cohort study. Therapeutic Advances in Cardiovascular Disease, 18. https://doi.org/10.1177/17539447241285136

Vancouver

Palazzuoli A, Pirrotta F, Cartocci A, Delcuratolo E, Dini FL, Correale M, et al. Effects of sacubitril/valsartan on renal function and outcome in patients with heart failure and reduced ejection fraction: an Italian cohort study. Therapeutic Advances in Cardiovascular Disease. 2024;18. doi:10.1177/17539447241285136

BibTeX
@article{Palazzuoli2024,
  author = {Palazzuoli, Alberto and Pirrotta, Filippo and Cartocci, Alessandra and Delcuratolo, Elvira and Dini, Frank Loyd and Correale, Michele and Dattilo, Giuseppe and Masarone, Daniele and Scelsi, Laura and Ghio, Stefano and Tocchetti, Carlo Gabriele and Mercurio, Valentina and Brunetti, Natale Daniele and Nodari, Savina and Barillà, Francesco and Ambrosio, Giuseppe and Carluccio, Erberto},
  title = {Effects of sacubitril/valsartan on renal function and outcome in patients with heart failure and reduced ejection fraction: an Italian cohort study},
  journal = {Therapeutic Advances in Cardiovascular Disease},
  year = {2024},
  volume = {18},
  doi = {10.1177/17539447241285136}
}
Kostenlos starten →